Meet the Aalto-Helsinki iGEM team 2024!

Greetings from Aalto-Helsinki iGEM team 2024, we are delighted to share with you a little about us and our project scope.

You probably have heard of iGEM at this point or never heard of it; rest assured, we’ve got you covered. iGEM is the right platform for you whether you have a background in biology or feel like that specialty paired with biology can create something useful. International Genetically Engineered Machine (iGEM) originates from Massachusetts Institute of Technology (MIT) in Boston, USA 2003, where students designed biological systems to make cells blink. This university design course became a summer competition with five teams in 2004. Twenty years later, it’s grown to 400+ teams from 45+ countries.

Nowadays, iGEM provides a platform for students from different fields to engage themselves in a challenging saga to design and implement innovative projects using experimental work, modelling applications, and cutting-edge design techniques to create a solution to a pressing issue of their choosing that they deem synthetic biology can offer an answer for. We highly encourage you to read more about iGEM on their website: https://igem.org/.

Aalto-Helsinki iGEM team 2024

From forming our team in February, we noticed that although we were nine different people from various fields, we shared a common passion: channeling our knowledge and expertise to the medical field. Even though we did not know which specific area we wanted to focus on, we needed at least a sense of direction and began the story.

We came across compelling statistics directing us toward cancer during the topic ideation process. This was because research showed us that even though science has made groundbreaking advances in treating cancer, it is still amongst the top five disease groups contributing to the total burden of disease. Moreover, global cancer incidents are projected to increase by 77%, which means a total of 35 million annual cases by 2050. Therefore, we conclude that cancer remains a pressing issue affecting not only people diagnosed with cancer but also their family and friends, so we would like to put our efforts into finding a solution that can help alleviate this ever-growing problem.

Figure 1: The LLPS Based Delivery of DOX would promote the cancer regression capability of the drug while negating the cardiotoxicity element of it.

After evaluating the feasibility of different ideas and consulting experts, we got inspired by one of the ongoing research projects at Aalto University. This research explores the existing adhesive proteins naturally found in mussel foot and spider silk, which have many biomedical uses. After thoroughly investigating the different applications, we understood that the drug delivery potential aligns more with our initial idea. Therefore, we started developing our bioadhesive-inspired LLPS-based drug delivery system.

Since our main target is cancer and developing a more sophisticated treatment option, we selected a widely used chemotherapeutic agent, named Doxorubicin to test our system and determine whether we can deliver it in a targeted and controlled manner. One of the main drawbacks of this drug is that it causes cardiotoxicity because it also targets normal cells. Therefore, we chose this drug to test our drug delivery system to determine whether we can deliver Doxorubicin locally.

Figure 2: A Two Component System designed to have a Target Component and Drug Component, forming a coacervate upon binding through the SpyTag/SpyCatcher leads to a more targeted and controlled release of the drug. Once the target component through the tumor homing peptide binds to its receptor on the target (cancer) cell, the system will be endocytosed allowing the drug to be released based on the pH environment of the cancer cell leading to cell death.

But is that all?

Although engineering biology is an important part of the iGEM, Engineers should operate at the interface between science and society. Therefore, the key part of this competition is how we can interact and engage with the world and the community that we are targeting. This is called Human practices in the context of the iGEM competition. For this purpose, we have been consulting with stakeholders including industry experts and researchers. We also plan to conduct interviews with medical personnel and cancer patients so we can get a better understanding of the impact of our project in the real world.

So far, we also collaborated with Heureka by holding a workshop for one of their exhibitions. We also participated in the TuKoKe event by TEK as the jury in order to advance and motivate youngsters in using their scientific knowledge for creating and innovating new solutions. Some of our team members also had the opportunity to attend one of the early iGEM meet-ups, the BFH 2024 where they had the chance to showcase our project to others, get suggestions, attend various workshops of the different elements of iGEM. This also gave us a chance to network with different people and even form potential collaborations with other iGEMers.

If you are interested in knowing more about our project and journey, you can check here (https://linktr.ee/aaltohelsinki) to visit our webpage, social media and blog.

We appreciate you taking the time to read!

We would like to express our gratitude to the Helsinki Institute of Life Science (HiLIFE) and the entire University of Helsinki for their support of the iGEM team and its project. Their assistance has been crucial to our ability to take part in the iGEM competition and program. So far, it has been an incredible opportunity and experience for all of us!

Meet the Aalto-Helsinki iGEM team 2023!

We are the Aalto-Helsinki iGEM team 2023!

We are a very diverse group of 10 students and here you can find about us and our project.

What is iGEM?

Welcome to the exciting world of synthetic biology! At the forefront of this rapidly developing interdisciplinary field is the International Genetically Engineered Machine (iGEM) competition, which originated from the prestigious Massachusetts Institute of Technology (MIT) in Boston, USA. Synthetic biology has enormous potential applications in fields such as medicine, food, agriculture, and energy. iGEM challenges students from around the world to design and implement innovative projects using experimental work, modelling applications, and cutting-edge design techniques, all within a short time frame. To learn more, please visit the official website: https://igem.org/

What is our idea?

Our team was born in February 2023, and shortly thereafter, we initiated our ideation process. Discovering a problem to address in our common interest proved more challenging than expected. Following intense ideation sessions, we came up with two proposals, which we subsequently presented to several experts. Consequently, the team reached a consensus to merge these ideas and address two pressing global challenges: plastic waste, and food scarcity.

The scale of plastic waste pollution is alarming, with over 350 million tons of plastics manufactured annually, and over 70% of plastic waste accumulating in landfills and oceans. This poses a significant environmental threat to ecosystems, marine life, and human health. Without any further changes to current policies, global plastic waste generation is projected to triple to one billion metric tons by 2060. Currently, the goal of plastic recycling is to reduce the need for primary plastic production. The competition between virgin plastics market and recycled plastics make recycling less attractive, since newly produced plastic has a higher relative material efficiency due to the ongoing availability of lower-cost feedstock.

Simultaneously, global food security remains a pressing concern, with over 820 million people undernourished and the need to increase food production by 70% before 2050. Conventional methods are insufficient to meet this growing demand. Focusing on the nordic countries, most of the agricultural activity focuses on meat production, even though it is a well known fact that it has a huge carbon footprint, and takes up double the resources than plant based food production. As the demand for food protein continues to rise, the development of novel and sustainable protein sources becomes environmentally and economically significant. There is great potential for producing protein-rich feed or food additives in the form of algae, yeasts, fungi and plain bacterial cellular biomass. They have a lower environmental footprint compared with other plant or animal-based alternatives.

We are focused on a circular economy system, aiming to reduce waste and utilise resources more efficiently by converting waste into valuable proteins. Our objective is to develop an optimised enzymatic plastic depolymerization system and demonstrate the feasibility of protein production utilising polyethylene terephthalate (PET) as the primary source.

Our project, PET-2-Protein, aims to develop a proof-of-concept approach for converting PET into proteins. Naturally occurring PETase enzymes are able to break down PET plastics into monomers such as terephthalic acid (TPA) and ethylene glycol (EG). Enzymatic degradation of plastic waste is an eco-friendly alternative to chemical plastic recycling. Our research aims to address the fundamental issue of plastic waste by focusing on plastic reduction. Consequently, we do not only design an optimised system for producing plastic-degrading enzymes but also optimise the enzymatic depolymerization of PET into TPA and EG, and finally, the microbial conversion of those monomers into proteins.

More about iGEM

iGEM is not only about designing our project. Using synthetic biology to address real-world problems requires thoughtful engagement with the world. In iGEM, this is referred to as Human Practices: thinking deeply and creatively about whether a synthetic biology project is responsible and good for the world. Throughout our project design we have contacted various experts and companies whose expertise shared similarities with PET-2-Protein, who have helped us to refine protocols and objectives. We have discussed several matters such as practicalities related to our methodology, the different uses that our end product could have and the ethical implications related to our work. Moreover, we are also focused in community outreach and science communication, addressing different audiences so that they can get to know our project, synthetic biology and iGEM. Our team is preparing a “science for children” workshop in Heureka as well as a collaboration with The Science Basement.

If you are interested in knowing more about our project and journey, you can visit our webpage, social media and blog.

Thank you for reading!

Our team wants to thank HiLIFE and the University of Helsinki for supporting the iGEM team and its project. Their support has been essential for us in order to participate in the iGEM program and competition. It has been an amazing experience and opportunity for all of us so far!

Meet the Aalto-Helsinki iGEM team 2022!

Hello! We are the Aalto-Helsinki iGEM team 2022 and here is a little bit about us and about our project.

First things first, what is iGEM?

iGEM stands for “international genetically engineered machine” and is a global synthetic biology competition between more than 350 teams around the world. We are a team of 10 highly-motivated students from both Aalto University and the University of Helsinki. The combined Aalto-Helsinki team has existed since 2014, but the team members are different every year. Last February, the 2021 Team chose us as the new members for the coming year, and since then we have been brainstorming about what our project should be. 

Every year, the team picks a research idea and spends the summer break implementing it in the lab, and then presenting the results at the Grand Jamboree (which this year will take place in Paris in October). As you can see, we have a very short time frame to organize, visualize, and prove our idea!

 

What is our idea?

After a lot of back-and-forth between several promising ideas, we decided to target biofilms on chronic wounds. Chronic wounds are found in 15 % to 25 % of diabetes patients and often lead to increased morbidity, mortality in general decreasing the quality of life, and are therefore of high public health concern. 

The environment of chronic wounds is usually low in oxygen (hypoxic) and thereby causes decreased immune activity. Therefore, bacteria can easily settle there, leading to the formation of biofilms. Biofilms are structural communities of bacteria that are usually tolerant to host defences and antibiotics. This is an issue for the patient, because treatment is more difficult.

Biofilms form when bacteria settle on the wound site, and their presence attracts even more bacteria through a process called quorum sensing. Quorum sensing is defined as population density measurement and a form of inter-microbial communication in the biofilm. The process of quorum sensing specifically works through bacteria releasing small molecules or peptides that other bacteria can take up, thereby sensing the presence of the other bacteria. Furthermore, bacteria can also auto-induce themselves via these peptides or molecules: indeed, auto-induction is a positive feedback-loop in which bacteria signal to themselves to produce even more of these quorum sensing peptides or molecules, through which further downstream gene activity and more biofilm build-up is achieved.

Our central aim is to target this mechanism to disrupt the formation of more biofilms.

For this we want to utilize DARPins. DARPin stands for designed ankyrin repeat proteins. They are genetically engineered peptides that mimic antibodies. We want to design DARPins that bind to the quorum sensing peptides released by the bacteria, which should prevent the “communication” between bacteria and obstruct the further build-up of biofilm. The end result we envision is for our designed DARPins to be used in combinatorial therapy with antimicrobial agents against biofilms, as blocking their signalling should make the bacteria more sensitive to such antimicrobials. 

 

Is that all?

In fact, iGEM is a lot more than just the research aspect. In addition to our main project, we also focus on developing different collaborations, as well as community outreach and science communication. The latter aspect is called Human Practices and represents a key foundation of the iGEM competition. As part of this, we are currently talking to many different experts in the field, including front-line medical staff, and are very happy to learn more about the practical considerations of wound healing. We will also prepare and hold a workshop at Heureka, and collaborate with The Science Basement. We plan to give a talk on the 24th of September during the European Biotech Week. We furthermore continue the Aalto-Helsinki iGEM podcast that was established last year.

So, if you want to know how everything is going throughout our project, you can follow us there or visit our blog.

 

Thank you for reading and thank you to HiLIFE!

Lastly, we also want to thank HiLIFE and the University of Helsinki for supporting us and our idea during the iGEM program and for enabling us to join this competition. We are very happy to be part of iGEM and cannot wait to get started, working to make our theories a reality!